

ZMK (23) 5/07, S. 314 ff.

Dr. Markus R. Fussnegger

Möglichkeiten der pharmakologischen Therapie bei CMD

1. Albuquerque RJ et al. Cerebral activation during thermal stimulation of patients who have burning mouth disorder: an fMRI study. *Pain* 122, 223-34. Epub 2006 Apr 24 (2006)
2. Amadio P et al., Nonsteroidal antiinflammatory drugs: Tailoring therapy to achieve results and avoid toxicity; *Postgrad Med* 93(4), 73-97 (1993)
3. Azad SC et al. The potassium channel modulator flupirtine shifts the frequency-response function of hippocampal synapses to favour LTD in mice. *Neurosci Lett* 370,186-190 (2004)
4. Bakke M et al. Morphine application to peripheral tissues modulates nociceptive jaw reflex. *Neuroreport* 9, 3315-9 (1998)
5. Bolton WW. Scientific rationale for specific inhibition of COX-2. *J of Rheumatol* 25, 2-7 (1998)
6. Bresalier RS et al. Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial (APPROVe Trial). *N Engl J Med* 352, 1092-102 (2005)
7. Chen YW et al. Intrathecal tri-cyclic antidepressants produce spinal anesthesia. *Pain* 112, 106-12 (2004)
8. Cheng JK, Chiou LC. Mechanisms of the Antinociceptive Action of Gabapentin. *J Pharmacol Sci* 100, 471-486 (2006)
9. Dao TTT, Mellor A. Sensory disturbances associated with implant surgery. *Int J Prosthodontics* 11, 462-9 (1998)
10. Diatchenko L et al. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. *Hum Mol Genet* 14, 135-43 (2005)
11. Emery P et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. *Lancet* 354, 2106-11 (1999)
12. Estler CJ. *Pharmakologie für Zahnmediziner*. 4.Aufl. Stuttgart: Schattauer-Verlag, 1993
13. European Medicines Agency (EMA). Public statement: European Medicines Agency announces regulatory action on COX-2 inhibitors. London: Press Office, 17 February 2005
14. Finnerup NB et al. Algorithm for neuropathic pain treatment: An evidence based proposal. *Pain* 118, 289-305 (2005)
15. Food and Drug Administration (FDA). FDA Public Health Advisory: FDA announces important changes and additional warnings for COX-2 selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). April 7, 2005
16. Forssell H et al. Sensory dysfunction in burning mouth syndrome. *Pain* 99, 41-7 (2002)

17. Freesmeyer WB, Fussnegger MR, Ahlers MO. Diagnostic and therapeutic-restorative procedures for masticatory dysfunctions. *GMS Curr Top Otorhinolaryngol Head Neck Surg* 2005;4:Doc19
18. Gillen C et al. Affinity, potency and efficacy of tramadol and its metabolites at the cloned human μ -opioid-receptor. *Naunyn-Schmiedeberg's Arch Pharmacol* 362, 116-121 (2000)
19. Gobbi M, Mennini T. Release studies with rat brain cortical synptosomes indicate that tramadol is a 5-hydroxytryptamine uptake blocker and not a 5-hydroxytryptamine releaser. *Eur J Pharmacol* 370, 23-26 (1999)
20. Göbel H et al. Reduktion der spastischen Muskeltonuserhöhung bei Multipler Sklerose durch das Non-opioidanalgetikum Flupirtin. Eine randomisierte, doppelblinde Cross-over Studie. *Schmerz* 13, 324-31 (1999)
21. Haas DA. An Update on analgesics for the management of acute postoperative dental pain. *J Can Dent Assoc* 68, 476-82 (2002)
22. Hinck D, Koppenhofer E. Tolperisone – a novel modulator of ionic currents in myelinated axons. *Gen Physiol Biophys* 20, 413-29 (2001)
23. Kim H, Dionne RA. Genetics, Pain and Analgesia. *Pain clinical updates. International Association for the Study of Pain (IASP) XIII(3)*, 1-4 (2005)
24. Koh H, Robinson PG. Occlusal adjustment for treating and preventing temporomandibular joint disorders. *Cochrane Database of Systematic Reviews* 2003, Issue 1. Art. No.: CD003812. DOI: 10.1002/14651858.CD003812
25. Kornhuber J et al. Flupirtine shows functional NMDA receptor antagonism by enhancing Mg²⁺ block via activation of voltage independent potassium channels. *J Neural Transm* 106, 857-67 (1999)
26. Lauria G et al. Trigeminal small-fiber sensory neuropathy causes burning mouth syndrome. *Pain* 115, 332-7 (2005)
27. List T et al. Intra-articular morphine as analgesic in temporomandibular joint arthralgia/osteoarthritis. *Pain* 94(3), 275-82 (2001)
28. Luther F. TMD and occlusion part II. Damned if we don't? Functional occlusal problems: TMD epidemiology in a wider context. *Br Dent J* 202 (1):E3; discussion 38-9 (2007)
29. Magnusson T, Egermark I, Carlsson GE. A prospective investigation over two decades on signs and symptoms of temporomandibular disorders and associated variables. A final summary. *Acta Odontol Scand* 63(2), 99-109 (2005)
30. McAdam BF et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2. *Proc Natl Acad Sci USA* 96, 272-77 (1999)
31. McQuay HJ et al. A systematic review of antidepressants in neuropathic pain. *Pain* 68, 217-27 (1996)
32. Mense S. Mechanismen der Chronifizierung von Muskelschmerz. *Orthopäde* 33, 525-532 (2004)
33. Moore N et al. Tolerability of ibuprofen, aspirin and paracetamol for the treatment of cold and flu symptoms and sore throat pain. *Int J Clin Pract* 56, 732-4 (2002)

34. Moore RA et al. Quantitative systematic review of topically applied non-steroidal anti-inflammatory drugs. *BMJ* 316, 333-8 (1998)
35. Okeson JP., *Bell's Orofacial Pains*, 6th edit, Quintessence Publishing Co, Inc., 2005
36. Onghena P, Van Houdenhove B. Antidepressant-induced analgesia in chronic nonmalignant pain: a meta-analysis of 39 placebo-controlled studies. *Pain* 49, 205-19 (1992)
37. Pleuvry BJ, Lauretti GR. Biochemical Aspects of chronic pain and its relationship to treatment. *Pharmacol Ther* 71, 313-24 (1996)
38. Samwel HJA et al. The role of helplessness, fear of pain and passive pain-coping in chronic pain patients. *Clin J Pain* 22, 245-51 (2006)
39. Scala A et al. Update on Burning Mouth Syndrome: Overview and patient management. *Crit Rev Oral Bio Med* 14, 275-91 (2003)
40. Schmitter M et al. The prevalence of myofascial pain and its association with occlusal factors in a threshold country non-patient population. *Clin Oral Invest* DOI 10.1007/s00784-007-0116-1
41. Sindrup SH., Jensen TS., Antidepressants for neuropathic pain. In Hansson PT. et al (Eds.) *Neuropathic pain: Pathophysiology and Treatment. Progress in Pain Research and Management*, IASP Press Vol.21, 169-183 (2001)
42. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. *Am J Med* 105(1B), 315-385 (1998)
43. Solomon SD et al. Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention (APC Trial). *N Engl J Med* 352, 1071-80 (2005)
44. Spencer CJ, Gremillion HA. Neuropathic orofacial pain: proposed mechanisms, diagnosis and treatment considerations. *Dent Clin North Am* 51, 209-224 (2007)
45. Svensson P et al. Effect of systemic versus topical nonsteroidal anti-inflammatory drugs on postexercise jaw-muscle soreness: a placebo-controlled study. *J Orofacial Pain* 11, 353-62 (1997)
46. Tölle TR. Chronischer Schmerz. In: Herdegen T, Tölle TR, Bähr M. *Klinische Neurobiologie. Molekulare Pathogenese und Therapie von neurologischen Erkrankungen*. Spektrum Akademischer Verlag GmbH Heidelberg Berlin Oxford, 1997
47. Türp JC et al. Recommendations for the standardized evaluation and classification of painful temporomandibular disorders: an update. *Schmerz* 20(6), 481-9 (2006)
48. Urquhart E, Central analgesic activity of nonsteroidal antiinflammatory drugs in animal and human pain models; *Sem Arth Rheumat* 23(3), 198-205 (1993)
49. Vickers ER, Cousins MJ. Neuropathic orofacial pain Part 1 – Prevalence and Pathophysiology. *Aust Endod J* 26, 19-26 (2000)
50. Villanueva L, Dickenson AH, Ollat H (Eds). *The pain system in normal and pathological states: a primer for clinicians. Progress in Pain Research and Management*, IASP Press Vol.31 (2004)
51. Waldman HJ., Centrally acting skeletal muscle relaxants and associated drugs; *J Pain Symptom Manag* 9(7), 434-41 (1994)